AP NEWS

Innovations in Chemotherapy Personalization, Cell Transplants, Multi-drug Resistance Studies, and Adult Stem Cell Regeneration, 2018 Study - ResearchAndMarkets.com

December 17, 2018

DUBLIN--(BUSINESS WIRE)--Dec 17, 2018--The “Innovations in Chemotherapy Personalization, Cell Transplants, Multi-drug Resistance Studies, and Adult Stem Cell Regeneration” report has been added to ResearchAndMarkets.com’s offering.

The Genetic Technology TechVision Opportunity Engine (TOE) presents trends across chemotherapy personalization, cell transplantation, multi-drug resistance studies, and adult stem cell regeneration. The corresponding clinical trials scenario related to monoclonal antibody drugs for autoimmune diseases is also depicted.

Key Topics Covered:

1. Recent Advances in Chemotherapy Personalization, Cell Transplants, Multi-drug Resistance Studies and Adult Stem Cell Regeneration

Chemotherapy Genetic Interaction Map for Personalized Treatment

Pancreatic Cell Transplant Capable of Vascularization

Decoding Acinetobacter Baumannii’s Multi-drug Resistance

Adult Stem Cell Regeneration by Fasting

2. Clinical Trial Analysis and Key Contacts

Clinical Trial Analysis of Monoclonal Antibody Drugs for Autoimmune Diseases

Key Contacts

For more information about this report visit https://www.researchandmarkets.com/research/dwt685/innovations_in?w=4

View source version on businesswire.com:https://www.businesswire.com/news/home/20181217005322/en/

CONTACT: ResearchAndMarkets.com

Laura Wood, Senior Press Manager

press@researchandmarkets.com

For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

Related Topics:Stem Cells

KEYWORD:

INDUSTRY KEYWORD: HEALTH BIOTECHNOLOGY ONCOLOGY PHARMACEUTICAL

SOURCE: Research and Markets

Copyright Business Wire 2018.

PUB: 12/17/2018 06:28 AM/DISC: 12/17/2018 06:28 AM

http://www.businesswire.com/news/home/20181217005322/en

AP RADIO
Update hourly